ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in ...

Inbrija (levodopa) is a brand-name inhaler prescribed for Parkinson’s disease. The cost of the drug, with and without insurance, can depend on several factors, such as whether Inbrija has a savings ...

Acorda Therapeutics has launched a streaming commercial for Inbrija, a four-year-old rescue inhaler for Parkinson’s sufferers, delivered only to viewers who have self-identified as being impacted in ...

ARDSLEY, N.Y. & PANAMA CITY--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Biopas Laboratories today announced that they have entered into distribution and supply agreements to ...

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and ...